Pfizer’s Apixaban gets nod from KFDA

Pfizer Korea said that the Korea Food and Drug Administration have approved its Eliquis (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Pfizer Inc. co-developed the drug with Bristol-Myers Squibb, which will share the profits.
The drug was approved based on two studies that showed better outcomes for patients t...